Alnylam initiated an outperform at BMO on RNAi pipeline
· seekingalpha.com
BMO initiates Alnylam at outperform with $318 target, highlighting RNAi pipeline, ATTR growth, and phase 3 assets. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...